Loss of Good Sleep Linked to All-Cause Mortality
A US study shows that nearly two-thirds of the population had suboptimal 5-year sleep duration trajectories with a resultant 29% increase in risk of all-cause mortality.
Read ArticleA US study shows that nearly two-thirds of the population had suboptimal 5-year sleep duration trajectories with a resultant 29% increase in risk of all-cause mortality.
Read ArticleA study from the Lupus Hopkins Cohort shows that systemic lupus erythematosus (SLE) patients with pericarditis are at risk for recurrence, and likely to be younger patients, with uncontrolled disease, and linkage to higher doses of oral prednisone.
This
JAMA Dermatology reports a retrospective cohort study from Johns Hopkins reviewing mimic of dermatomyositis (DM), suggesting that DM and especially clinically amyopathic DM (CADM) are commonly and initially misdiagnosed as inflammatory skin disease (ISD).
The study was undertaken to
Read ArticleA study from the FDA's adverse event reporting system (FAERS or Medwatch) database identified cases of drug induced systemic lupus erythematosus (SLE) in patients receiving tumor necrosis factor-α (TNF-α) inhibitors - a paradoxical reaction to common antiinflammatory biologic agents.
Read ArticleIn a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.
Read ArticleScience and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct
Read ArticleA cohort study of shows that postoperative weight loss with antiobesity medications significantly reduced the risk of 5-year and 10-year revision among patients with obesity undergoing hip or knee replacement.
Read ArticleDr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleA novel machine learning framework – Mal-ID – can decipher an individual’s immune system’s record of past infections and diseases, according to a new study, providing a powerful tool with the potential for diagnosing autoimmune disorders, viral infections, and vaccine responses with precision
Read ArticleA post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI. Adalimumab was equally effective in patients
Read ArticleBMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter Clinical Dermatology Conference in Hawaii
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
The manufacturer, Anaptys, issued a press release regarding rosnilimab, a drug being developed for use in
Read ArticleThe AMA has just published the results of a U.S. Physician survey and shown MD attitudes have positively shifted regarding the use of artificial intelligence (AI) in healthcare.
The AMA defines AI has having a wide range of potential use cases in healthcare, including but not limited to
Read ArticleDr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read ArticleLinks:
Traditionally, rheumatologists have often been deferential to the non-articular concerns in RA to other providers, though these issues are often left unaddressed. What role do rheumatologists have in the management of multimorbidity in our patients?
Read ArticleLinks:
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
Read ArticleLinks: